Although the cause of salt-sensitivity in DS rats is unknown, it has been shown that adrenalectomy will prevent salt-induced hypertension.
R ats have been selectively bred for susceptibility and resistance to the hypertensinogenic effects of dietary salt by Dr. L.K. Dahl (DS and DR rats, respectively) and further inbred to homozygosity by Dr. J.P. Rapp (SS/Jr and SR/Jr). 12 Although the cause of salt-sensitivity in DS rats is unknown, it has been shown that adrenalectomy will prevent salt-induced hypertension. 3 This establishes that intact adrenal function is at least permissive, and possibly provocative, in regard to hypertension in DS rats.
DS rats appear to have abnormal adrenal cortical function. DS adrenal glands are large, and plasma renin and aldosterone levels are low, suggesting that they may be suppressed from excessive mineralocorticoid activity. 4 " 7 DS rats have markedly different adrenal steroid production manifest by increased adrenal 18-hydroxylation of deoxycorticosterone (DOC) to form 18-OH-DOC. 48 This results in increased 18-OH-DOC production rates and plasma levels, which are two to three times higher than those in DR rats. 4 - 6 Even though 18-OH-DOC in large doses causes salt retention, it is a very weak mineralocorticoid with only 0.1% of the receptor-binding affinity of aldosterone. 9 -12 Based on these estimates of mineralocorticoid activity, elevated 18-OH-DOC secretion is unlikely to account for salt-sensitivity in DS rats.
Even though 18-OH-DOC as a mineralocorticoid is too weak to account for salt-sensitivity in DS rats, the abnormal gene responsible for increased 18-OH-DOC cosegregates with the blood pressure response to salt of DS rats. Based on quantitative genetic techniques, this genetic locus is believed to be one of the approximately 2-4 genetic loci involved in DS rat salt-sensitivity. 1314 Although the exact product of this locus is unknown, one possibility is the 18-hydroxy- 14 It is believed that since the pituitary regulates corticosterone levels, a compensatory increase in adrenocorticotropic hormone (ACTH) corrects the relative corticosterone deficiency, leading to normal levels of corticosterone.
Conversely, urinary 19-nor-DOC is increased in SS/Jr. 1718 19-Nor-DOC is a much more potent saltretaining corticoid than 18-OH-DOC, and it is equipotent with aldosterone in mineralocorticoid bioassay systems.
19
- 21 To determine the contribution of 19-nor-DOC to the salt-sensitivity of SS/Jr, we inhibited 19-nor-DOC biosynthesis by using an aromatase inhibitor that selectively blocks adrenal 19-hydroxylation without interfering with 11/3-or 18-hydroxylation.
Methods
Breeding colonies of SS/Jr and SR/Jr were generously provided by Dr. John Rapp, Medical College of Ohio, Toledo, Ohio. SS/Jr animals were descendants from over 24 generations of brother/sister matings. All rats were maintained on a low salt diet (0.3% NaCl; Teklad, Madison, Wis.) during mating and pregnancy and afterward for future matings. Offspring of the SS/Jr were weaned at 28 days of age at which time the sexes were separated. These animals were transferred to metabolic cages and maintained on a low salt diet and tap water in a constanttemperature environment with a 12-hour light/dark cycle. Pellets containing either vehicle or 120 mg 19-acetylenic-androst-4-ene,3,17-dione (19-AA) (MDL 18,962, Merrill Dow Research Institute, Cincinnati, Ohio) were implanted subcutaneously at 42, 52, and 62 days of age (see Table 1 for protocol). Pellets were made by Innovative Research of America, Toledo, Ohio. Fifteen female and eight male SS/Jr received 19-AA pellets; 23 female and 15 male SS/Jr were controls and received vehicle pellets.
These pellets were designed to deliver approximately 10-12 mg/day, and at the end of the experiment, no visible remaining pellet could be found at the injection site. High salt diet (8% NaCl) was begun at the time of the first pellet and continued throughout the remainder of the study. Tail-cuff systolic blood pressures (SBP) of the conscious, unstressed animals were recorded using a physiograph monitor (desk model 4B, Narco BioSystems, Houston, Tex.) in a sound-resistant, constant-temperature room starting at 3 weeks of treatment. Rats were habituated to the procedure during several training sessions. Urine was collected from male animals on days 34 through 41 and 50 through 57. Sodium azide was added as a preservative. The samples were frozen and pooled to complete a week's collection. Aliquots of urine were extracted and purified by thin-layer chromatography before radioimmunoassay for corticosterone, aldosterone, and 19-nor-DOC using procedures that have been previously described. 
Results
Because of the small size of the young male rats, SBP could not be measured before the first pellets were implanted. Eight days after pellet implantation and high salt diet, SBP was reduced in both male and female 19-AA-treated groups compared with control SS/Jr (Figure 1 ). In male SS/Jr, SBP was reduced with 19-AA at 15 and 22 days after pellet implantation, but SBP was not different than that of control SS/Jr at 30 days after implantation. Similarly, in female SS/Jr, SBP was lower at 15 and 22 days after implantation, but a steady trend of increasing SBP was observed. SBP in the females could not be measured on day 30 because of technical reasons.
Urinary corticosteroids were measured in male animals before and after the first pellet implant ( Figure  2 ). Urinary free 19-nor-DOC increased with age in both vehicle and 19-AA-treated SS/Jr between 34 and 50 days of age. 19-Nor-DOC levels after pellet implantation were mildly reduced in 19-AA-treated SS/Jr (0.05 <p< 0.10). Urinary free aldosterone levels decreased in both vehicle and 19-AA-treated SS/Jr after the high salt diet was started at 42 days of age. Survival was much better in the 19-AA-treated SS/Jr group. At the end of the study, only 36% of the vehicle-treated SS/Jr were alive whereas 100% of the 19-AA-treated SS/Jr survived.
Discussion
The data from this study demonstrate that the aromatase inhibitor 19-AA attenuates the hypertensive effects of a high salt intake in male and female SS/Jr and modestly reduces 19-nor-DOC excretion. Beginning 10 days after implantation, the antihypertensive effects of 19-AA gradually decreased in the female rats; this took 23 days in male rats. The reason for loss of antihypertensive effect was probably dissipation of 19-AA, which may have been accelerated in the female animal. Clearly, 19-AA is antihypertensive in this animal in both sexes, but whether it is related to 19-nor-DOC inhibition is not certain. 19-AA is a mechanism-based inhibitor that has been designed to selectively inactivate enzymes that oxygenate steroids at the C19 position. 2425 19-AA was first used as an inhibitor of aromatase, an enzyme that catalyzes oxidative removal of the C19-methyl from androgenic steroids. 26 - 27 Inhibition of aromatase decreases the conversion of androgens to estrogens resulting in lower estrogen levels. Lowered estrogen production, however, is unlikely to explain the antihypertensive effect since this was observed in male as well as female SS/Jr.
The biosynthesis of 19-nor-DOC is analogous to the aromatization of androgens to estrogens and therefore may be susceptible to 19-AA inhibition. Both reactions have an initial C19-hydroxylation, followed by multiple C19-oxygenation, resulting in loss of the C19-methyl group. Adrenal 19-hydroxylase differs from aromatase since the A-ring is not aromatized. Instead, three C19-oxygenations result in the formation of the C19-alcohol, C19-aldehyde, and C19-acid intermediates. 28 - 29 Ultimately, the C19-substituent is lost, resulting in a 19-norcorticoid, 19-nor-DOC.
19-AA inhibits the adrenal 19-hydroxylation of DOC in both isolated mitochondria and reconstituted purified enzyme preparations. 30 19-AA decreases 19-nor-DOC excretion and blood pressure in the spontaneously hypertensive rat (SHR) compared with vehicle-treated SHR. 31 This antihypertensive effect is similar to the present report in the SS/Jr, but the decrease in 19-nor-DOC was less in the SS/Jr. The difference in inhibition by 19-AA of 19-nor-DOC could be attributed to differences in delivery systems of 19-AA. In the SHR study, 19-AA (10 mg) was given by daily injection, whereas in the present SS/Jr study, 19-AA (120 mg) was given as a 10-day subcutaneous pellet. Although at the end of the study all of the pellet appeared to have been absorbed, it was not possible to tell whether the pellet had been completely absorbed before the end of the 10-day study period.
Mechanism-based inhibitors possess a latent reactive function that becomes unmasked at the enzyme's active site. Such an inhibitor is extremely specific because it inactivates only enzymes for which it is a substrate. will theoretically only inactivate enzymes that oxygenate steroids at the C19 position.
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25
- 30 Other closely related reactions, including the adrenal 11/3-and 18-hydroxylases, are not inhibited to the same extent by 19-AA. This is based on the finding that 11/3-and 18-hydroxylation of DOC is not inhibited by 19-AA in vitro and that urinary corticosterone and aldosterone levels are not decreased in rats receiving 19-AA in
VJVO.25,30,31
It is possible that antihypertensive effects of 19-AA in the SS/Jr and SHR may be through mechanisms other than inhibition of 19-nor-DOC production. Future studies should perhaps include restoration of 19-nor-DOC levels in these 19-AA-treated animals to ascertain whether this will nullify the antihypertensive effects. It is also possible that 19-AA may be inhibiting other known and unknown hypertensinogenic 19-oxysteroids and 19-norsteroids, including 19-norprogesterone, 19-noraldosterone, and 19-OH-androstenedione. 34 - 41 Only 19-nor-DOC, however, has been found to be elevated in the SS/Jr. Whatever the mechanism, 19-AA is clearly antihypertensive in the SS/Jr and further studies are warranted.
